$-0.07 EPS Expected for CytoDyn Inc. (CYDY)

March 20, 2018 - By Adrian Mccoy

 $ 0.07 EPS Expected for CytoDyn Inc. (CYDY)

Analysts expect CytoDyn Inc. (OTCMKTS:CYDY) to report $-0.07 EPS on April, 12.They anticipate $0.01 EPS change or 16.67 % from last quarter’s $-0.06 EPS. The stock decreased 6.64% or $0.0456 during the last trading session, reaching $0.6415. About 489,931 shares traded or 80.44% up from the average. CytoDyn Inc. (OTCMKTS:CYDY) has 0.00% since March 20, 2017 and is . It has underperformed by 16.70% the S&P500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. The company has market cap of $134.01 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.